Key result
One-hour doxorubicin infusion fails to reduce cardiotoxicity risk over shorter infusion in canine cancer.
Why the study?
Doxorubicin causes cumulative cardiotoxicity, but the incidence of clinical cardiotoxicity in dogs receiving doxorubicin had not been determined.
What is the incidence of and what are the risk factors for clinical cardiotoxicity in dogs receiving doxorubicin?
Cohort (n=494)
No
What is the incidence of and what are the risk factors for clinical cardiotoxicity in dogs receiving doxorubicin?
The overall incidence of clinical doxorubicin-induced cardiotoxicity in dogs is low (4.0%), but risk is significantly increased by higher cumulative doses, higher body weight, early echocardiographic/electrocardiographic changes, and breed predisposition.
Answers are grounded in this paper and cite their sources.
Low incidence supports breed- and dose-specific monitoring in dogs; leaves open whether infusion duration affects risk.
BACKGROUND: Doxorubicin (DOX) can cause cumulative cardiotoxicity in dogs, but the incidence of clinical cardiotoxicity in dogs receiving DOX has not been determined. HYPOTHESIS/OBJECTIVES: To determine if the duration of DOX infusion influences the incidence of cardiotoxicity, to characterize the incidence of clinical cardiotoxicity in dogs during or after DOX chemotherapy, and to identify any risk factors associated with cardiotoxicity. ANIMALS: Four-hundred ninety-four dogs that received at least 1 dose of DOX for the treatment of cancer. METHODS: Retrospective study of dogs that received DOX from 2006 to 2015. RESULTS: Of 494 dogs, 20 (4.0%) developed clinical cardiotoxicity. The duration of DOX infusion was not significantly associated with clinical cardiotoxicity, whereas a higher cumulative dose of DOX, higher body weight, decreases in fractional shortening after 5 doses of DOX, and development of ventricular premature contractions were significantly associated with clinical cardiotoxicity. High-risk breeds for developing dilated cardiomyopathy had an incidence of 15.4%, whereas low-risk breeds had an incidence of 3.0%. CONCLUSIONS AND CLINICAL IMPORTANCE: Although the duration of DOX infusion did not influence the incidence of cardiotoxicity, premature contractions and decreases in fractional shortening should raise concern for the development of clinical cardiotoxicity. Overall, the incidence of clinical DOX-induced cardiotoxicity is low, but Boxers and other breeds at high risk for dilated cardiomyopathy may be at an increased risk.
No takes yet. Share an insight, caveat, or question.
Hallman et al. (2019) conducted a cohort in Cancer (n=494). 1-hour doxorubicin infusion vs. 10-15 minute doxorubicin infusion was evaluated on Development of clinical cardiotoxicity (p=0.08). In dogs receiving doxorubicin for cancer, the overall incidence of clinical cardiotoxicity was 4.0%, and a 1-hour infusion did not significantly reduce the risk compared to a 10-15 minute infusion.
Synapse has enriched 10 related papers. Consider them for comparative context: